Rhabdomyolysis following single administration of pembrolizumab: Is severe immune-reaction a marker for durable treatment response?
Saved in:
Main Authors: | Varun Khetan (Author), Erin A. Blake (Author), Marcia A. Ciccone (Author), Koji Matsuo (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2021-02-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
SJS/TEN immune-related dermatologic reaction secondary to immune checkpoint inhibitor pembrolizumab in skin of color
by: A.B. Pierre, et al.
Published: (2023) -
Long-term durable responses after pembrolizumab immunotherapy for recurrent, resistant endometrial cancer
by: John K. Chan, et al.
Published: (2020) -
A complete durable response of vaginal clear cell carcinoma with pembrolizumab: A case report
by: Hector S. Porragas-Paseiro, et al.
Published: (2023) -
Single immunization with an influenza hemagglutinin nanoparticle‐based vaccine elicits durable protective immunity
by: Shiho Chiba, et al.
Published: (2024) -
Durable partial response to pembrolizumab, lenvatinib, and letrozole in a case of recurrent uterine carcinosarcoma with ESR1 gene amplification
by: Jenny L. Soiffer, et al.
Published: (2024)